GlassScriptPhysician profile
George M Ozborn
NPI 1275577710
$633.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.80 · 2020: $46.46 · 2021: $518 · 2022: $15.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.36 | 2019-2021 | |
| Amarin Pharma, INC. | $84.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $61.79 | 2021 | |
| Abbott Laboratories | $29.40 | 2021 | |
| Pfizer INC. | $29.12 | 2019-2021 | |
| Lilly USA, LLC | $26.81 | 2021 | |
| Seqirus USA INC | $19.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.76 | 2021 | |
| Hikma Pharmaceuticals USA | $17.75 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.48 | 2021 | |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Abbvie INC. | $15.97 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $13.55 | 2019 | |
| Almatica Pharma LLC | $12.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ozborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.